Night Blindness Causes, Types, Treatment Options & Symptoms

What Is Night Blindness?

Night blindness (nyctalopia) is the inability to see well in low light or darkness, with relatively preserved vision in normal daylight conditions. The term is technically a misnomer: most people with night blindness are not totally blind at night, but their functional vision in low-light environments is well below what their daytime acuity would suggest. Most people do not appreciate that activities such as driving after sunset, finding their way through a dimly lit room, and walking down stairs after dark become difficult, hazardous, or impossible.

The model involves the eye’s rod photoreceptors. They are specialized cells in the retina that help us detect shapes, movement, and contrast in low light. They are concentrated in the peripheral retina and work best in dimly lit conditions, exactly when the cone photoreceptors that handle color and fine detail become far less effective. Nutritional deficiency, inherited degeneration, drug toxicity, or acquired retinal disease can impair rod function and lead to deterioration of night vision. This deterioration can be profound and sometimes occurs without the person realizing it.

Night blindness is a symptom of more than a dozen clinically distinct conditions, from vitamin A deficiency (preventable and completely reversible with early treatment) to retinitis pigmentosa (progressive and no treatment) to drug-induced retinal toxicity (preventable with monitoring). Vitamin A deficiency remains a major public health problem in India, especially among children under five years and pregnant or lactating women belonging to nutritionally vulnerable populations. The early and accurate diagnosis of the cause of night blindness determines whether management is supplementation or complex, specialist-led retina management.

Here are some of the most common signs of night blindness you may experience:

• Difficulty seeing clearly in dimly lit rooms, restaurants, cinema halls, or during power outages.
• Highly decreased night vision and driving ability: Glare from headlights and streetlights still makes it difficult to see surrounding road details.
• A noticeably slower adjustment when moving from a bright environment to a dim one (impaired dark adaptation).
• Bumping into furniture, tripping on steps, or losing footing in low-light conditions.
• Difficulty recognizing faces or reading expressions in low light, but can easily recognize the same people in daylight.
• A progressively narrowed field of vision: Objects at the periphery of the visual field become invisible in dim light before being difficult to see in bright light (characteristic of retinitis pigmentosa)
• Visible clinical signs of severe vitamin A deficiency are foamy, white, triangular spots on the white of the eye (Bitot’s spots).
• Nighttime glare, halos, or starbursts around point light sources (car headlights, streetlamps, etc.).
• Difficulty locating moving objects such as a vehicle, ball, or child in low light or darkness.

What Are the Types of Night Blindness?

We classify night blindness according to two parameters: time of onset (congenital or acquired) and progression (stationary or progressive). This classification determines the urgency of investigation, the investigations chosen, and the nature of the long-term management plan.

Commonly classified types of night blindness include the following:

• Congenital Stationary Night Blindness (CSNB): Present from birth and non-progressive. Caused by genetic mutations affecting rod photoreceptor signaling pathways. Visual acuity may be normal or mildly reduced. Includes X-linked, autosomal dominant, and autosomal recessive subtypes. Diagnosis rests on a characteristic electroretinogram (ERG) pattern combined with fundus examination.
• Oguchi Disease: A rare autosomal recessive form of stationary night blindness associated with a distinctive golden or silver-gray metallic sheen to the fundus in the light-adapted state, the Mizuo-Nakamura phenomenon, which normalizes after prolonged dark adaptation. Caused by mutations in the arrestin or rhodopsin kinase genes.
• Fundus Albipunctatus: Stationary night blindness with multiple white dots scattered across the fundus on examination, caused by abnormally slow regeneration of visual pigment (rhodopsin). Non-progressive. Associated with mutations in the RDH5 gene. Night vision improves after prolonged dark adaptation in a dark room.
• Retinitis Pigmentosa (Progressive Night Blindness): The most clinically important progressive inherited cause of night blindness globally. RP begins with rod photoreceptor degeneration, producing night blindness and progressive peripheral visual field constriction (“tunnel vision”) and eventually involves cone photoreceptors, causing loss of central vision. The fundus shows the classic triad: bone-spicule pigmentation at the mid-peripheral retina, optic disc pallor, and attenuated retinal blood vessels. RP is genetically heterogeneous, with autosomal dominant, autosomal recessive, and X-linked forms, and affects approximately 1 in 4,000 people worldwide.
• Vitamin A Deficiency Night Blindness (Nutritional, Acquired): The most common preventable cause of night blindness globally and a significant public health priority in India. Vitamin A (retinol) is the direct precursor of rhodopsin, the light-sensitive pigment in rod photoreceptors. Without adequate vitamin A, rhodopsin cannot be synthesized, and rod function fails. Night blindness is the earliest and most sensitive clinical manifestation of deficiency, preceding any visible corneal or conjunctival changes and fully reversible with prompt treatment.
• Myopia-Associated Night Blindness: High myopia (typically above -6 dioptres) stretches and thins the retina, reducing the functional density of rod photoreceptors per unit area and impairing peripheral retinal function. Night vision is disproportionately affected relative to the degree of daytime visual acuity loss.
• Cataract-Associated Night Blindness: An advanced or posterior subcapsular cataract reduces the total amount of light reaching the retina and dramatically increases glare from point sources at night. This condition is completely and immediately reversible with cataract surgery, one of the most rewarding surgical outcomes for patients presenting with night vision complaints.
• Drug-Induced Night Blindness: Chloroquine and hydroxychloroquine (used for malaria, rheumatoid arthritis, and lupus), quinine, and phenothiazine antipsychotics are documented to cause progressive retinal toxicity that primarily manifests as impaired night vision. Regular retinal monitoring is the established standard of care for all patients on long-term therapy with these agents.

What Are the Common, Uncommon & Underlying Causes of Night Blindness?

Night blindness arises when the eye’s rod photoreceptors cannot produce, sustain, or effectively signal through rhodopsin, the visual pigment that enables dim-light vision. The cause may be nutritional, genetic, drug-related, structural, or driven by systemic disease. Identifying it precisely is essential because the cause determines whether treatment is immediate, supplementary, surgical, or oriented toward long-term management and monitoring.

Here are some reasons for night blindness:

1.Common Causes

• Vitamin A deficiency: The dominant preventable cause worldwide. Vitamin A is biochemically indispensable for rhodopsin synthesis. Populations at highest risk in India include children under five years of age, pregnant and lactating women, individuals with chronic malabsorption (Crohn’s disease, celiac disease, or post-bariatric surgery), and those following severely calorie- or fat-restricted diets. Night blindness is the first and most sensitive clinical indicator of vitamin A deficiency, appearing well before any visible ocular surface changes develop. Treatment at this stage produces complete restoration of rod function.
• Retinitis Pigmentosa: The leading inherited cause globally. Progressive rod-then-cone photoreceptor degeneration produces night blindness as its earliest and most prominent symptom, typically first manifesting in the first or second decade of life. A family history of visual loss or blindness, progressive night blindness, and peripheral field constriction together constitute the clinical triad that warrants urgent electroretinographic investigation.
• High Myopia: Short-sightedness above -6 diopters results in retinal stretching, peripheral thinning, lattice degeneration, and reduced rod photoreceptor density per unit retinal area, typically impairing dim-light vision in cases of high axial myopia.
• Cataract: A posterior subcapsular cataract, the subtype most commonly causing night blindness, sits directly in the light path through the optical axis. It reduces total light transmission and creates significant glare from point light sources, with symptoms most severe at night. Cataract surgery resolves this completely.
• Uncorrected Refractive Error: Inadequate spectacle or contact lens correction adds optical blur to an already challenging low-luminance visual environment, compounding the difficulty of night vision beyond the primary rod dysfunction.

2.Uncommon Causes

• Advanced Glaucoma: Significant optic nerve damage from advanced, inadequately controlled glaucoma reduces signal transmission from photoreceptors to the visual cortex, resulting in peripheral visual field loss that impairs night vision in proportion to the degree of optic neuropathy.
  Diabetic Retinopathy: Retinal ischemia and microvascular damage in diabetic retinopathy impair rod function, particularly in the peripheral retina, forming night vision difficulties proportional to the extent and location of retinal involvement.
• Zinc Deficiency: Zinc is a cofactor for the enzyme that converts vitamin A (retinol) to its active aldehyde form (retinal) within the photoreceptor cell. Isolated zinc deficiency impairs night vision even when dietary vitamin A intake is adequate, through a secondary effect on the vitamin A metabolic pathway.
• Post-Retinal Detachment Surgery: Persistent rod photoreceptor dysfunction following retinal detachment repair, particularly when the superior retina was involved, may result in residual night vision impairment and anatomical reattachment, requiring a specific discussion during preoperative counseling.

3.Underlying & Systemic Causes

• Malabsorption syndromes: Crohn’s disease, celiac disease, cystic fibrosis, short-bowel syndrome, and post-bariatric surgery can impair the absorption of fat-soluble vitamins, including vitamin A, and lead to deficiency and night blindness as a serious and under-recognized complication in these patient groups.
• Chronic Liver Disease: The liver is the main storage site of vitamin A in the body. Vitamin A stores are significantly depleted in advanced liver disease, cirrhosis, and chronic hepatitis despite apparently adequate dietary intake. Night blindness may be the first presenting symptom of hepatic depletion of vitamin A.
• Usher Syndrome: An autosomal recessive inherited condition combining sensorineural hearing loss with retinitis pigmentosa. It is one of the most significant causes of combined deaf-blindness worldwide. Night blindness is characteristically the first ocular symptom, appearing in the first or second decade of life. Early identification enables rehabilitation planning, communication support, genetic counseling, and enrollment in research and therapeutic programs.
• Drug Toxicity (Chloroquine & Hydroxychloroquine): Chronic use of these antimalarial and antirheumatic agents leads to progressive retinal toxicity with a characteristic pattern of “bull’s eye” maculopathy. Night blindness is an early warning symptom. The standard of care for all patients on long-term therapy is annual monitoring with OCT and multifocal electroretinography.
• Vitamin A Deficiency in Pregnancy: Pregnant and lactating women in nutritionally vulnerable settings are highly susceptible to night blindness owing to increased vitamin A requirements during pregnancy and lactation and inadequate dietary intake, with implications not only for maternal ocular health but also for fetal and neonatal vitamin A status, immune function, and risk of mortality from infection.

When Should You Visit an Ophthalmology Specialist for Night Blindness?

Night blindness is not a symptom to dismiss as age-related vision change or attribute to needing a stronger prescription. Some of its causes are immediately and fully reversible; others are progressive without specialist intervention; and some signal a systemic nutritional or metabolic state that has serious consequences beyond the eyes. A specialist assessment resolves the uncertainty and initiates the correct management pathway.

Visit your ophthalmology specialist if these signs or aspects of night blindness are present:

• If you notice night blindness worsening steadily over months or years, seek a genetic evaluation immediately and identify potential retinal degeneration.
• Night blindness in a child or teenager is a typical inherited retinal dystrophy that begins in the first two decades of life.
• Night blindness is accompanied by a progressive narrowing of side vision (peripheral field loss or tunnel vision).
• Night blindness in a pregnant or lactating woman: nutritional deficiency at this stage has consequences for both mother and baby.
• Night blindness in a child under five with poor dietary intake, recurrent infections, or visible conjunctival or corneal changes.
• Foamy white patches on the white of the eye (Bitot’s spots), alongside difficulty with night vision.
• Usher’s syndrome symptoms, such as alternating vision and hearing loss, are important to look for since night blindness rarely occurs alone. Children with balance issues, such as frequent stumbling or delayed walking, should be monitored by families and asked about a family history of similar issues. Recognizing these signs helps patients move beyond an eye exam to genetic testing for a precise diagnosis.
• Night blindness in a patient on long-term chloroquine, hydroxychloroquine, or phenothiazine therapy.
  Night blindness following bariatric surgery, chronic bowel disease, or significant liver disease.
• Night blindness in a patient with a family history of retinal disease, inherited blindness, or visual field loss.
• Any sudden or rapid onset of night vision difficulty excludes retinal detachment, acute metabolic causes, or drug toxicity as urgent considerations.

Diagnostic Approach for Night Blindness

The diagnostic approach to night blindness starts with a detailed clinical and family history, proceeding stepwise from the cornea and lens to the retina and the systemic metabolic picture. Electroretinography, the gold-standard functional test for rod photoreceptor integrity, is not available in most general eye care settings, and specialist referral is essential for any patient with unexplained or progressive night blindness.

Here are the specialist-approved diagnostic steps:

• Before any examination: Gather comprehensive clinical and family history, including age at onset; progression rate; family history of vision issues or retinal disease, hearing problems, and systemic conditions (such as malabsorption, liver disease, and diabetes); diet; current medications (notably chloroquine, hydroxychloroquine, and phenothiazines); and obstetric history for female patients.
• Best-corrected visual acuity (BCVA): Assesses baseline daylight vision. Notably, preserved daytime BCVA coupled with severe night vision problems strongly suggests a rod-specific disorder rather than a general optical impairment.
• Visual field testing (using Goldmann perimetry or Humphrey automated perimetry): Accurately maps the peripheral visual field. Progressive constriction characterized by a ring scotoma advancing to tunnel vision is a hallmark of retinitis pigmentosa.
• Dilated fundus exam: Conducted with pupils dilated, inspecting the optic disc, retinal vessels, and periphery. Diagnostics include bone-spicule pigmentation, narrowed arterioles, and disc pallor. In vitamin A deficiency, conjunctival Bitot’s spots and corneal dryness are evident. Retroillumination may reveal posterior subcapsular cataracts.
• Electroretinogram (ERG): Considered the gold standard for assessing rod and cone function. The dark-adapted (scotopic) ERG specifically evaluates rod activity. A marked decrease or absence of scotopic responses confirms rod dysfunction early, aiding in diagnosing retinitis pigmentosa and distinguishing it from non-progressive conditions.
• Dark adaptometry: Measures how quickly and completely the eye adapts in darkness after light exposure. Elevated thresholds in dark adaptation indicate rod dysfunction, caused by vitamin A deficiency or RP, helping differentiate from optical issues like cataracts or refractive errors.
• Serum vitamin A (retinol): Directly measures vitamin A stores. Levels under 0.70 µmol/L confirm deficiency; 0.70–1.05 µmol/L indicates marginal status, especially in vulnerable groups.
• Serum zinc & carotene: Zinc deficiency hampers vitamin A metabolism; low carotene signals poor dietary intake. These tests help guide nutritional interventions.
• Optical coherence tomography (OCT): Offers detailed retinal layer imaging, assessing photoreceptor integrity, detecting macular changes such as cystoid edema or epiretinal membranes, and monitoring chloroquine toxicity over time.
• Fundus autofluorescence (FAF): Non-invasively maps lipofuscin in the retinal pigment epithelium, highlighting areas of photoreceptor loss and disease progression patterns in RP and related dystrophies.
• Genetic testing (targeted gene panels or exome sequencing): Confirms specific inherited retinal dystrophy mutations, aids counseling, and determines eligibility for gene therapies. It is increasingly central to clinical diagnosis.
• Blood tests for glucose, HbA1c & liver function: Identify systemic issues, such as diabetic retinopathy and vitamin A depletion.
• Malabsorption evaluation: Includes celiac serology, inflammatory markers, stool fat tests, and bowel imaging if malabsorption is suspected as the cause of vitamin A deficiency.

How to Treat Night Blindness?

Treatment for night blindness must target the specific identified cause. Vitamin A supplementation rapidly and completely restores rod function in nutritional deficiency. Cataract surgery immediately and permanently resolves night blindness from a posterior subcapsular lens opacity. Retinitis pigmentosa, by contrast, currently has no cure. Its progression can be monitored, its genetic basis characterized, its treatable complications managed, and its functional consequences meaningfully mitigated with further rehabilitation. All prescription interventions listed here must be administered under specialist supervision.

Clinical treatments & rehabilitative strategies for underlying causes include the following:

• Vitamin A supplementation (prescription-only): High-dose vitamin A is administered orally or, for patients with absorption problems, intramuscularly following WHO-recommended protocols and under close specialist supervision. In children under five with clinical signs of deficiency, treatment is a medical priority that must begin without delay. Dietary counseling to increase intake of vitamin A-rich foods, such as liver, eggs, full-fat dairy products, green leafy vegetables, and orange or yellow-fleshed fruits and vegetables, supports recovery and prevents recurrence.
• Zinc supplementation: Where zinc deficiency is confirmed as a contributing factor, specialist-guided supplementation restores the vitamin A metabolic pathway and contributes to rod photoreceptor function recovery.
• Optimized spectacle or contact lens correction: Correcting uncorrected or under-corrected myopia or astigmatism improves the optical quality available to rod photoreceptors in dim light, the simplest, most accessible, and most commonly underutilized improvement for night vision in the general population.
• Cataract surgery: For cataract-related night blindness, surgical removal of the opacified lens and implantation of an intraocular lens restores full light transmission to the retina. Night vision improvement after successful cataract surgery for a posterior subcapsular cataract is typically immediate and substantial, and among the most gratifying surgical outcomes in ophthalmology.
• Retinitis Pigmentosa current management: No curative therapy currently exists for RP in routine clinical practice. Management focuses on regular retinal monitoring (fundus examination, OCT, and visual field testing every 6–12 months); identification and treatment of associated complications (cystoid macular edema responds to oral carbonic anhydrase inhibitors, prescription-only; cataracts are removed surgically); low-vision rehabilitation; orientation and mobility training; and genetic counseling for the patient and their family.
• Gene therapy (for eligible RPE65-associated inherited retinal dystrophy): Voretigene neparvovec is approved for RPE65-associated Leber congenital amaurosis, and select RP subtypes meet specific criteria. The specialist will advise on current trial and approved therapy eligibility based on genetic characterization. Gene therapies for additional RP mutations are in active clinical trial phases.
• Retinal prosthetics (for end-stage RP): Electronic retinal implants offer partial restoration of light perception in profoundly vision-impaired RP patients who meet specific structural and functional eligibility criteria. The specialist discusses these options within the context of the individual patient’s residual retinal architecture.
• Intraocular pressure reduction (for glaucoma-associated night blindness): Prescription-only topical IOP-lowering medications, selective laser trabeculoplasty, or surgical filtration procedures slow the progression of optic nerve damage, preserving the remaining visual field, including peripheral night vision.
• Anti-VEGF therapy & laser photocoagulation (for diabetic retinopathy): Intravitreal anti-VEGF injections (prescription-only) stabilize and may partially reverse retinal ischemia-related changes; targeted laser photocoagulation reduces the risk of further photoreceptor loss from neovascular complications.
• Medication withdrawal or substitution (for drug-induced retinal toxicity): The retinal specialist coordinates with the prescribing physician, rheumatologist, psychiatrist, or infectious disease specialist to assess whether dose reduction, substitution with a less retinotoxic agent, or monitored continuation is most appropriate for the patient’s overall clinical situation.
• Low-vision aids & adaptive strategies: Anti-reflective spectacle coatings that reduce glare, yellow-tinted lenses for night driving (where legally & clinically appropriate), high-luminance portable lights, electronic magnification devices, and screen-reading technologies all help patients with stable or progressive night blindness maintain independence, functional capacity, and quality of life.

What If Night Blindness Is Left Untreated?

The importance of not leaving night blindness untreated is clear, measurable, and often avoidable if the underlying cause is treatable. A delayed diagnosis of progressive inherited conditions slams shut windows for adaptive planning, genetic counseling, and eligibility for emerging therapies.

Some possible complications of untreated night blindness include the following:

• Corneal damage & permanent blindness from severe vitamin A deficiency: Night blindness is stage one. Untreated vitamin A deficiency progresses through conjunctival xerosis, corneal xerosis, corneal ulceration, and keratomalacia, the liquefaction of the cornea, producing permanent, irreversible blindness. This progression can occur with alarming speed in malnourished children and represents a preventable pediatric emergency.
• Delayed diagnosis of retinitis pigmentosa: Without ERG-based specialist diagnosis, affected individuals lose years during which genetic counseling could inform reproductive decisions, low-vision rehabilitation could protect occupational function, and eligibility for gene therapy or research participation could be established.
• Falls, road accidents & occupational injuries: Severely impaired night vision results in profound spatial disorientation in low-light environments. The risk of falls in older adults, road traffic accidents as a pedestrian or driver, and workplace injuries rises significantly with untreated nyctalopia.
• Progression of chloroquine-induced retinal toxicity: Patients on chloroquine or hydroxychloroquine without regular retinal monitoring who present with night blindness as an early warning sign will, if the medication is left unchanged, develop progressive bull’s-eye maculopathy with permanent central vision loss. Early detection and medication review prevent this outcome.
• Missed treatable complications of RP: Cystoid macular edema and visually significant cataract are both common, treatable complications of retinitis pigmentosa that accelerate central vision loss. Without regular specialist monitoring, these complications progress undetected and untreated, producing avoidable additional visual impairment.
• Social isolation & loss of independence: The inability to navigate safely in dim environments restricts social outings, independent travel, driving, and outdoor activity after sunset. The resulting social withdrawal, forced dependence on others, and loss of autonomy have been documented to have cumulative impacts on mental health and quality of life.
• Missed systemic diagnosis: Night blindness when it occurs only from vitamin A deficiency signals a systemic nutritional deficit that also compromises immune function, epithelial barrier integrity throughout the body, and, in pregnant women, fetal development, neonatal vitamin A stores, and infant immune competence. Addressing only the ocular symptom without the full systemic picture misses the most clinically significant aspect of the condition.